Brief: GC Biopharma Launches ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid For Adults, An Immune Globulin For The Treatment Of Primary Humoral Immunodeficiency (PI) - Now Available In The US Marketplace
09/09/2024 11:06
Sept 9 (Reuters) - GC Biopharma Corp 006280.KS :
* GC BIOPHARMA LAUNCHES ALYGLO™ (IMMUNE GLOBULIN
INTRAVENOUS,
HUMAN-STWK) 10% LIQUID FOR ADULTS, AN IMMUNE GLOBULIN FOR THE
TREATMENT OF PRIMARY HUMORAL IMMUNODEFICIENCY (PI) - NOW
AVAILABLE IN THE US MARKETPLACE
Source text for Eikon: ID:nPn8blWGTa
Further company coverage: 006280.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GC Biopharma
See all newsBrief: Gc Biopharma Q2 Operating. Profit 1.7 Billion Won, Down 93.8% Y/Y
Brief: Gc Biopharma Corp 006280.Ks - Q1 Operating. Profit 11.7 Billion Won, Up 46% Y/Y
Brief: Green Cross Corp Q3 Operating Profit 29.2 Billion Won, Down 26.3% From Year Earlier
Brief: GC Biopharma gets CMO rights for shingles vaccine from Curevo Vaccine
Brief: Gc Biopharma Receives Marketing Authorization For Barycela In Vietnam